Table 1 Patient characteristics and laboratory measurements of patients with rhabdomyolysis and septic shock.
From: Angiopoietin-2 adsorption attempt with the cytokine adsorber cytosorb in critically ill patients
Whole cohort | Patients with septic shock | Patients with rhabdomyolysis | p-value | |
|---|---|---|---|---|
n (%) or median [IQR] | ||||
Patient characteristics | ||||
Number of patients | 26 | 9 | 17 | |
Age (years) | 54 [41; 63] | 56 [48; 64] | 51 [39; 62] | 0.367 |
Gender: male/female | 20 (77)/6 (23) | 7 (78)/2 (22) | 13 (76)/4 (24) | 0.668 |
Weight (kg) | 80 [74; 94] | 75 [70; 80] | 80 [75; 110] | 0.263 |
Height (m) | 1.79 [1.72; 1.84] | 1.8 [1.72; 1.85] | 1.77 [1.72; 1.82] | 0.833 |
BMI (kg/m2) | 25 [22; 30] | 25 [23; 26] | 26 [22; 33] | 0.241 |
28-days mortality | 15 (58) | 7 (78) | 8 (47) | 0.138 |
SAPS-II at the day of treatment | 72 [61; 80] | 62 [59; 72] | 76 [62; 82] | 0.065 |
Renal replacement therapy | ||||
CVVHD (CiCa®)/ CVVHDF (MultiBic®, post-dilution) | 17 (65)/9 (35) | 3 (33)/6 (67) | 14 (82)/3 (18) | 0.02 |
Blood flow (ml/min) | 100 [100; 200] | 150 [100; 250] | 100 [100; 200] | 0.241 |
Dialysate flow (ml/h) | 2000 [2000; 2000] | 2000 [2000; 2500] | 2000 [2000; 2000] | 0.916 |
Substitute flow (if CVVHDF) | 1900 [0; 2000] | 1800 [0; 2000] | 1001 [1000; 2250] | 0.6 |
Ultrafiltration (ml/h) | 50 [0; 125] | 0 [0; 135] | 75 [0; 127.5] | 0.187 |
Urine output during treatment | 0 [0; 20] | 0 [0; 50] | 0 [0; 20] | 0.491 |
Time on dialysis before CS (h) | 48.2 [15,3; 202,6] | 11.8 [0; 252] | 69.3 [30,3; 227,3] | 0.077 |
Time between ICU admission and start CS (h) | 133.3 [25.5; 308] | 35 [13.7; 486] | 162 [44.3; 471.5] | 0.225 |
Laboratory parameters shortly before initiation of cytosorb | ||||
Angiopoietin-2 (pg/ml) | 21,653 [11,185; 33,839] | 31,916 [14,017; 36,448] | 20,661 [10,953; 31,680] | 0.241 |
Creatinine (mg/dl) | 1.9 [1.5; 2.5] | 1.9 [1.1; 2.3] | 1.8 [1.5; 2.5] | 0.56 |
Urea (mg/dl) | 75 [48; 100] | 38 [30; 63] | 86 [57; 100] | 0.034 |
Lactate (mmol/l) | 2.3 [1.7; 6.7] | 5.3 [2.3; 9.7] | 2.0 [1.7; 4.2] | 0.181 |
IL-6 (pg/ml) | 678 [67; 5607] | 10,092 [2520; 27,383] | 83 [51; 654] | < 0.001 |
CRP (mg/dl) | 8.8 [4.0; 15.9] | 26 [3.2; 36] | 7.4 [4.7; 12] | 0.312 |
LDH (U/l) | 1338 [554; 1940] | 1257 [523; 1749] | 1370 [660; 1962] | 0.56 |
Bilirubin (mg/dl) | 3,2 [1,5; 8,4] | 3.2 [0.8; 3.5] | 3.1 [1.7; 10.8] | 0.525 |
Myoglobin (ng/ml) | 17,130 [8400; 89,741] | 7700 [894; 12,791] | 44,666 [11,985; 106,009] | 0.018 |
Creatinkinase (U/l) | 4761.5 [840; 20,226.5] | 1628 [97; 22,000] | 14,466 [1363; 22,000] | 0.063 |
Clinical parameters shortly before initiation of cytosorb | ||||
Norepinephrine dosage (µg/kg/min) | 0.24 [0.11; 0.41] | 0.38 [0.27; 0.62] | 0.15 [0.07; 0.38] | 0.039 |
Fluid balance on day of CS treatment (ml/24 h) | 2615 [1022; 5720] | 6063 [3377; 7773] | 1173 [464; 4350] | 0.011 |
